Month: September 2012

September 26, 2012
B-LONG results positive for Biogen/SOBI

Wednesday 26 September 2013: Top-line results from the late-stage B-LONG trial suggest that Biogen/SOBIs’ long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) is effective for control and prevention of bleeding, routine prophylaxis, and perioperative management in people with haemophilia B. The multi-center, phase 3 B-LONG study included 123 male patients with haemophilia B aged 12 …

Read article
September 14, 2012
New kid on the block looks promising

Pro Bono Bio Group plc has successfully concluded its pre-clinical trials in haemophilia patients using the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The company claims the availability of its subcutaneous blood factors could make self-administration by patients at home much easier, leading to a significant improvement in …

Read article